Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cipla europe nv - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - 0.5mg/2.5 milligram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salbutamol and sodium cromoglicate

Κένυα - Αγγλικά - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - ipratropium bromide bp and levosalbutamol… - nebuliser solution - ipratropium bromide 500 mcg/2.5 ml and… - other decongestantsand other nasal preparations

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - ipratropium bromide monohydrate; salbutamol sulfate - nebuliser solution - 0.5mg/2.5 milligram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salbutamol and sodium cromoglicate

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - ipratropium bromide monohydrate ; salbutamol sulfate - nebuliser solution - 0.5mg/2.5 milligram - salbutamol and sodium cromoglicate

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide and albuterol sulfate inhalation solution 0.5 mg/3 mg per 3 ml patient's instructions for use read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide and albuterol sulfate inhalation solution 0.5 mg/3 mg per 3 ml  read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. storing your medicine store ipratrop

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sandoz inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

eon labs, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

proficient rx lp - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.